SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
biotech firesales
An SI Board Since August 2001
Posts SubjectMarks Bans
3661 167 0
Emcee:  dalroi Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3486Axovant's stock tumbles toward record low after disappointing drug trial resJulius Wong-1/8/2018
3485<statistically significantly worse> I wouldn't be surprised.Miljenko Zuanic-1/5/2018
3484Amazing and finally put them to sleep. I wish they had disclosed the p-value. Srkrw-1/5/2018
3483"Squlamine is finally DEAD, for real. After + 25 years. Did any fake-drug cBladerunner17-1/5/2018
3482RE: OHRP, finance.yahoo.com Ohr Pharmaceutical Announces Efficacy Results from Miljenko Zuanic21/5/2018
3481See Syros commentary . Scroll down a little ways and note Ozgur's commentstuck-12/12/2017
3480Strong rebound today ... i sold a few otm calls that got in the money for severasemi_infinite -12/12/2017
3479VistaGen (VTGN) off 35% on financing after a huge spike on a patent issuance. Ktuck-12/11/2017
3478AFMD off 17% this morning. I'm not sure why. Were the results presented atBladerunner17-12/11/2017
3477Syros (SYRS), a recent IPO, failed utterly at ASH this weekend, and is off 46% atuck-12/11/2017
3476I was looking at it yesterday and again today. There is hardly any call premiumsemi_infinite -12/6/2017
3475Neuralstem (CUR) off nearly 30%. Yesterday, it almost tripled on a well spun trituck-12/6/2017
3474Galectin (GALT) off 44% pre-market on NASH cirrhosis P2 fail (that is being spuntuck-12/5/2017
3473DBVT -50% AH because there was not enough differentiation from placebo A poll atnsaf-10/22/2017
3472FWIW, seeing twitter chatter regarding management's caginess regarding the ntuck-10/12/2017
3471ACRX down 60% on CRL. Is there value here? I thought Dsuvia would be approved.Bladerunner17-10/12/2017
3470Momenta (MNTA) off 16% as Mylan gets approval for both doses of generic Copaxonetuck-10/4/2017
3469Yeah, sector a bit split last couple of days Companies with best science and buscaram(o)uche-9/29/2017
3468Interesting as bio indexes churn a bit that THE JIMS stocks just exploding higheRobohogs-9/29/2017
3467See?? I'm so distracted that I didn't realize that Friedman was a part scaram(o)uche-9/28/2017
3466On MDGL... Personal tip to all: Never play poker with Paul Friedman when it coBiotech Jim-9/28/2017
3465Stupid. Stupid. Stupid. Stupid. Stupid. Stupid. Stupid. [graphic] Just some ssjemmeri29/28/2017
3464Geeeze. I've simply got to start paying attention. 3X in 1.5 months. Sescaram(o)uche-9/28/2017
3463ADXS/Adage addendum: investorshub.advfn.comDewDiligence_on_SI-9/26/2017
3462Real reason for severe ADXS sell-off the past few days: investorshub.advfn.comDewDiligence_on_SI-9/26/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News